This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A temporary halt to elective surgeries cut insurers’ expenses, although under federal law, the bulk of profits must eventually go to services or rebates for policy holders.
Two health-care giants, Cambia Health Solutions in Portland and BlueCross BlueShield of North Carolina in Durham, announced a partnership agreement on Tuesday that’s designed to save money and spur innovation.
A key Senate committee Wednesday launched a set of hearings intended to lead to a short-term, bipartisan bill to shore up the troubled individual health insurance market, but a diverse group of state insurance commissioners united around some solutions that were not necessarily on the table.
Health insurers have won powerful allies in a fight over federal subsidies that President Donald Trump has threatened to cancel for millions of people who buy insurance through the Affordable Care Act.
As top Republicans see it, a medical malpractice crisis is threatening U.S. health care: Frivolous lawsuits are driving up malpractice insurance premiums and forcing physicians out of business.
Six years into building its business around the Affordable Care Act, the nation’s $3 trillion health care industry may be losing that political playbook.
Industry leaders, like many voters, were stunned by the election of Donald Trump and unprepared for Republicans’ plans to “repeal and replace” Obamacare.
The Affordable Care Act transformed the medical system, expanding coverage to millions, injecting billions in tax revenue, changing insurance rules and launching ambitious experiments in quality and efficiency.
Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.
Buried in the fine print of many marketplace health plan documents is language that allows them to refuse to cover a range of services, many of which disproportionately affect women, a recent study found.
A new study takes a fresh measure of generic drugs’ price advantages, revealing how much more Medicare Part D patients shelled out in copayments for two popular brand-name drugs in 2013.
The result: 10.5 times more.
